Physician profile
Syed Malik
NPI 1184713992
$9,929.03
in general payments reported to CMS, 2019-2025
50 companies · $3,219 in 2025
The $3,219 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $827 · 2021: $989 · 2022: $473 · 2023: $1,368 · 2024: $1,706 · 2025: $3,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Travel and Lodging: $1,141 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,133.76 |
| Travel and Lodging | $1,141.28 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,734.90 | 2021-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,623.96 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $909.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.41 | 2019-2025 | Ofev |
| Axsome Therapeutics, INC. | $410.40 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $375.82 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $355.36 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $291.21 | 2019-2025 | Zerbaxa, Keytruda, Recarbrio |
| Genzyme Corporation | $276.27 | 2021-2025 | |
| Insmed, INC. | $275.28 | 2019-2025 | Brinsupri, Arikayce |
| Electromed, INC. | $249.97 | 2021-2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $243.75 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $218.64 | 2021-2025 | Hyqvia, Glassia, Cuvitru |
| Grifols USA, LLC | $212.82 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $202.39 | 2022-2025 | Dupixent |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.